APPLICATIONS RECEIVED 16 JUNE 2004
Published: 1-Dec-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Use of potent, selective and non-toxic C-Kit inhibitors for treating institial cystitis
AB Science 1427379*
Fluid-to-powder compsns
E-L Management 1427380*
Compsns and methods relating to prevention of chemotherapy-induced alopecia
Voellmy, Richard 1427383*
Drug delivery system
Schering 1427390*
Vascular occlusion solid-phase agent with immobilised platelet binding agent
Virexx Research; Stewart, Michael; Person, Roland; Noujaim, Antoine 1427391*
New self-emulsifying drug delivery system
AstraZeneca 1427392*
Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
Vasogen Ireland 1427394*
Stabilisation of active agents by formulation into nanoparticulate form
Elan Pharma International 1427395*
Dosage forms having prolonged active ingredient release
Lunamed 1427396*
Oily thixotropic formulations
F Hoffmann-La Roche 1427397*
Device for the administration of an active agent to the human skin
Coloplast 1427398*
Retinoid receptor pan-antagonists for stimulating chondrogenesis
The University of Western Ontario 1427399*
Triclosan dosage form
The North West University 1427400*
Method for reducing hypertension and heart failure
The Research Foundation of State University of New York 1427401*
Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
Cellular Sciences 1427402*
Valproic acid and derivatives for the combination treatment of human cancers, tumour metastasis and minimal residual disease
G2M Cancer Drugs 1427403*
Treatment of glial tumours with glutamate antagonists
Nedergaard, Maiken 1427404*
Inflammation-inhibiting compounds
Luger, Thomas 1427405*
Modulation of stat activity
University of Nottingham 1427406*
Fatty amine drug conjugates
Protarga 1427407*
Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or the TNF-a converting enzyme (TACE)
Bristol-Myers Squibb 1427408*
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
Schering 1427409*
Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone deterioration
Merckle 1427410*
(-)-1-(3,4-dichlorophenyl)-3-azabicyclo 3.1.0]hexane, compsns thereof, and uses as a dopamine-reuptake inhibitor
DOV Pharmaceuticals 1427411*
Methods of treating cytokine-mediated diseases
Boehringer Ingelheim Pharmaceuticals 1427412*
2-aroylimidazole compounds for treating cancer
Synta Pharmaceuticals 1427413*
Inhalation compsns comprising tricyclic 5,6-dihydro-9H-pyrazolo (3,4-C)-1,2,4-trazolo (4,3-alpha) pyridines
Pfizer 1427414*
Lactam-containing compounds and derivatives thereof as factor XA inhibitors
Bristol-Myers Squibb 1427415*
3-glyoxlylamideindoles for treating cancer
Synta Pharmaceuticals 1427416*
3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
Arpida 1427417*
Piperazinone compounds as anti-tumour and anti-cancer agents and methods of treatment
Yale University 1427418*
Improvement of the local compatibility during intravenous administration of 4-(4-(2-pyrrolocarbonyl)-1-piperazinyl)-3-trifluoromethylbenzoylguanidine
Boehringer Ingelheim Pharma 1427419*
Use of 4-pyridylmethylphthalazines for cancer treatment
Novartis 1427420*
2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
Amgen 1427421*
Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
AB Science 1427422*
Benzothiazepine ad benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment of hyperlipidaemia
AstraZeneca 1427423*
LPA receptor agonists and antagonists and methods of use
The University of Tennessee Research Corporation 1427424*
Method of treatment of obesity and paralysed muscle and ergogenic aids
Brigham Young University 1427425*
GPI-anchored cytokines
Greenville Hospital System 1427426*
Derivatives of partially desulphated glycosaminoglycans as heperanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
Sigma-Tau Industrie Farmaceutiche Riunite 1427427*
Apoptosis-mimicking natural vesicles and use thereof in medical treatment
Vasogen Ireland 1427428*
Compsns and methods for treating subjects with hyperglycaemia
Ohio University 1427429*
Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary system caused by sex hormones
Bionorica 1427430*
Bioadhesive compsns and methods for enhanced mucosal drug absorption
ISIS Pharmaceuticals 1427431*
Methods of healing or preventing inflammation damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4 analogues, isoforms and other derivatives
Regenerx Biopharmaceuticals 1427432*
Biodegradable implant comprising a polylactide polymer and a LH-RH analogue
AstraZeneca 1427433*
Anti-inflammatory agent
University of Strathclyde; The University Court of the University of Glasgow 1427434*
Methods for resensitising vancomycin resistant bacteria using agents which selectively cleave a cell wall depsipeptide
The Trustees of the City University of New York 1427435*
Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
Westgate Biological 1427436*
Oxyntomodulin for preventing or treating excess weight
Imperial College Innovations 1427437*
Inflammation modulatory compound comprising an endomorphin
The University of Bristol 1427438*
Gamma three protease
Merck & Co 1427439*
Composite superimmunogen for bifunctional vaccine use for the treatment of illnesses associated with a stromal tissue disorder
Neovacs 1427441*
